Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.
Rossini F, Terruzzi E, Verga L, Larocca A, Marinoni S, Miccolis I, Giltri G, Isella M, Parma M, Pogliani EM. Rossini F, et al. Among authors: terruzzi e. Support Care Cancer. 2005 Jun;13(6):387-92. doi: 10.1007/s00520-004-0753-8. Epub 2004 Dec 15. Support Care Cancer. 2005. PMID: 15599778 Clinical Trial.
Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.
Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P. Perseghin P, et al. Among authors: terruzzi e. Transfus Apher Sci. 2009 Aug;41(1):33-7. doi: 10.1016/j.transci.2009.05.011. Epub 2009 Jun 18. Transfus Apher Sci. 2009. PMID: 19540167
Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission.
Parma M, Viganò C, Fumagalli M, Colnaghi F, Colombo A, Mottadelli F, Rossi V, Elli E, Terruzzi E, Belotti A, Cazzaniga G, Pogliani EM, Pioltelli P. Parma M, et al. Among authors: terruzzi e. Mediterr J Hematol Infect Dis. 2015 Jun 1;7(1):e2015041. doi: 10.4084/MJHID.2015.041. eCollection 2015. Mediterr J Hematol Infect Dis. 2015. PMID: 26075048 Free PMC article.
Severe, reversible nelarabine-induced neuropathy and myelopathy.
Alberti P, Parma M, Pioltelli P, Pogliani EM, Terruzzi E, Stasia A, Doni E, Cecchetti C, Cavaletti G. Alberti P, et al. Among authors: terruzzi e. J Peripher Nerv Syst. 2016 Sep;21(3):154-6. doi: 10.1111/jns.12173. J Peripher Nerv Syst. 2016. PMID: 27117493 No abstract available.
Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
Dander E, De Lorenzo P, Bottazzi B, Quarello P, Vinci P, Balduzzi A, Masciocchi F, Bonanomi S, Cappuzzello C, Prunotto G, Pavan F, Pasqualini F, Sironi M, Cuccovillo I, Leone R, Salvatori G, Parma M, Terruzzi E, Pagni F, Locatelli F, Mantovani A, Fagioli F, Biondi A, Garlanda C, Valsecchi MG, Rovelli A, D'Amico G. Dander E, et al. Among authors: terruzzi e. Oncotarget. 2016 Dec 13;7(50):82123-82138. doi: 10.18632/oncotarget.13488. Oncotarget. 2016. PMID: 27893415 Free PMC article.
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making.
Civettini I, Zappaterra A, Granelli BM, Rindone G, Aroldi A, Bonfanti S, Colombo F, Fedele M, Grillo G, Parma M, Perfetti P, Terruzzi E, Gambacorti-Passerini C, Ramazzotti D, Cavalca F. Civettini I, et al. Among authors: terruzzi e. Br J Haematol. 2024 Apr;204(4):1523-1528. doi: 10.1111/bjh.19200. Epub 2023 Dec 9. Br J Haematol. 2024. PMID: 38070128 Free article.
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.
Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A, Barretta F, Terruzzi E, Mussetti A, Pini M, Bosi A, Dominietto A, Cascavilla N, Onida F, Narni F, Farina L, Rambaldi A, Corradini P. Dodero A, et al. Among authors: terruzzi e. Biol Blood Marrow Transplant. 2017 Jul;23(7):1102-1109. doi: 10.1016/j.bbmt.2017.03.031. Epub 2017 Apr 5. Biol Blood Marrow Transplant. 2017. PMID: 28390983 Free article. Clinical Trial.
35 results